BCACP Anticoagulation Management 2

Question 1

Which DOAC has the lowest proportion of renal elimination (~27%), making it most suitable in patients with chronic kidney disease?

Accepted Answer

Apixaban

Answer

Apixaban has approximately 27% renal elimination, the lowest among the four approved DOACs, compared to dabigatran (~80%), making it most favorable in CKD patients.

Question 2

Idarucizumab (Praxbind) is the FDA-approved specific reversal agent for which anticoagulant?

Accepted Answer

Dabigatran

Answer

Idarucizumab is a humanized monoclonal antibody fragment that specifically binds and neutralizes dabigatran's anticoagulant effect.

Question 3

Andexanet alfa (Andexxa) is FDA-approved for reversal of which anticoagulants in life-threatening bleeding?

Accepted Answer

Rivaroxaban and apixaban

Answer

Andexanet alfa is a modified recombinant Factor Xa decoy protein approved for reversing rivaroxaban and apixaban (both Factor Xa inhibitors) in life-threatening bleeding.

Question 4

According to AHA/ACC guidelines, oral anticoagulation is RECOMMENDED (not merely considered) for males with nonvalvular atrial fibrillation when their CHA2DS2-VASc score reaches:

Accepted Answer

2 or greater

Answer

AHA/ACC guidelines recommend oral anticoagulation for males with nonvalvular AF and CHA2DS2-VASc score of 2 or greater; a score of 1 makes anticoagulation reasonable but not definitively recommended.

Question 5

Which anticoagulant regimen is now preferred over LMWH for cancer-associated thrombosis in patients without high gastrointestinal or genitourinary bleeding risk?

Accepted Answer

Apixaban or rivaroxaban (direct oral anticoagulants)

Answer

Updated ISTH and ASCO guidelines recommend DOACs (apixaban or rivaroxaban) over LMWH as preferred therapy for cancer-associated thrombosis in appropriate patients.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP Anticoagulation Management 2